On July 7, 2026, Rigel Pharmaceuticals, Inc. in South San Francisco revealed that it awarded grants under the Rigel Pharmaceuticals, Inc. Inducement Plan. This plan was approved by the Compensation Committee of Rigel's Board of Directors. Rigel Pharmaceuticals, Inc. is listed on Nasdaq as RIGL.